A tumour suppressive relationship between mineralocorticoid and retinoic acid receptors activates a transcriptional program consistent with a reverse Warburg effect in breast cancer [0.03%]
一种肿瘤抑制关系通过盐皮质激素受体和视黄酸受体激活乳腺癌中与反向瓦伯格效应一致的转录程序
Tram B Doan,Vanessa Cheung,Colin D Clyne et al.
Tram B Doan et al.
Background: The role of nuclear receptors in both the aetiology and treatment of breast cancer is exemplified by the use of the oestrogen receptor (ER) as a prognostic marker and treatment target. Treatments targeting the...
A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations [0.03%]
代谢性乳腺癌的临床特点及分子异常综合述评
Tejaswini P Reddy,Roberto R Rosato,Xiaoxian Li et al.
Tejaswini P Reddy et al.
Metaplastic breast cancer (MpBC) is an exceedingly rare breast cancer variant that is therapeutically challenging and aggressive. MpBC is defined by the histological presence of at least two cellular types, typically epithelial and mesenchy...
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer [0.03%]
布帕利西姆巴(BKM120)(一种泛类I PI3K抑制剂)治疗转移性三阴乳腺癌二期临床研究
Ana C Garrido-Castro,Cristina Saura,Romualdo Barroso-Sousa et al.
Ana C Garrido-Castro et al.
Background: Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via loss of PTEN and/or INPP4B is common. Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. We...
Prognostic value of 18F-FDG PET and PET/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis [0.03%]
氟脱氧葡萄糖正电子发射断层扫描(X线计算机体层摄影)预测新辅助化疗后乳腺癌治疗反应的预后价值：系统性回顾和meta分析
Sangwon Han,Joon Young Choi
Sangwon Han
Background: We performed a systematic review and meta-analysis to evaluate the prognostic significance of 18F-FDG PET and PET/CT for evaluation of responses to neoadjuvant chemotherapy (NAC) in breast cancer patients. ...
Use of nonsteroidal anti-inflammatory drugs and breast cancer risk in a prospective cohort of postmenopausal women [0.03%]
一项绝经后女性前瞻性队列研究中非甾体抗炎药的使用与乳腺癌风险的关系
Manon Cairat,Marie Al Rahmoun,Marc J Gunter et al.
Manon Cairat et al.
Background: Although anti-inflammatory agents could theoretically have anticancer properties, results from cohort studies on nonsteroidal anti-inflammatory drugs (NSAIDs) and breast cancer (BC) risk are inconsistent. ...
COVID-19: a potential driver of immune-mediated breast cancer recurrence? [0.03%]
新冠肺炎：可能的免疫介导乳腺癌复发驱动因素？
Federica Francescangeli,Maria Laura De Angelis,Ann Zeuner
Federica Francescangeli
Severe coronavirus disease 2019 (COVID-19) causes a hyperactivation of immune cells, resulting in lung inflammation. Recent studies showed that COVID-19 induces the production of factors previously implicated in the reawakening of dormant b...
Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets [0.03%]
早期乳腺癌中局部和远处肿瘤休眠与浸润的T效应子亚群占优势相关
Hussein F Aqbi,Cara Coleman,Melika Zarei et al.
Hussein F Aqbi et al.
Background: Although breast cancer mortality is a result of distant recurrences associated with the establishment of tumor dormancy, current clinical practice guidelines recommend a wait and watch approach for tumor recur...
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial [0.03%]
体内质量指数对HER2阳性乳腺癌新辅助治疗疗效的影响-NeoALTTO研究的事后分析
Serena Di Cosimo,Luca Porcu,Dominique Agbor-Tarh et al.
Serena Di Cosimo et al.
Background: Obesity is a risk factor for breast cancer (BC) development, recurrence, and death. In view of this, we aimed to investigate the clinical value of obesity in BC patients treated with anti-HER2 therapies in the...
Differential kynurenine pathway metabolism in highly metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression [0.03%]
高侵袭性乳腺癌亚型中的不同犬尿氨酸代谢：超越IDO1诱导的免疫抑制作用
Benjamin Heng,Ayse A Bilgin,David B Lovejoy et al.
Benjamin Heng et al.
Background: Immunotherapy has recently been proposed as a promising treatment to stop breast cancer (BrCa) progression and metastasis. However, there has been limited success in the treatment of BrCa with immune checkpoin...
Pubertal timing and breast cancer risk in the Sister Study cohort [0.03%]
青春期发育时机与 Sister研究队列中的乳腺癌风险关联研究
Mandy Goldberg,Aimee A D&#x;Aloisio,Katie M O&#x;Brien et al.
Mandy Goldberg et al.
Background: Earlier age at menarche is an established risk factor for breast cancer. While age at menarche has been fairly stable over the past half-century, age at breast development (thelarche) has continued to decrease...